Charlie Bolten


Dr. Bolten is a Vice President of the St. Louis BioGenerator, a seed stage investment group. Bolten has extensive R&D experience having 10 years experience working at big pharmaceutical companies. Before joining the BioGenerator, Charlie held the position of Principal Scientist and Project Leader in the Pfizer Exploratory Immunobiology group, where he led a reverse pharmacology collaboration with PTC Therapeutics focusing on post-transcriptional regulation of T cell cytokines and was the Research Project Leader for small molecule discovery program targeting an effector T cell subtype-selective receptor.